Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells

References

• Collins VP. Gliomas. Cancer Surv 1998; 32: 37–51
   PubMedGoogle Scholar
• Kraemer DF, Fortin D, Neuwelt EA. Chemotherapeutic dose intensification for treatment of malignant brain tumors: Recent developments and futures directions. Curr Neurol Neurosci 2002; 2: 216–24
   PubMedGoogle Scholar
• Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and Glioblastoma Multiform. J Natl Cancer Inst 2001; 15;93: 1246–56
   Google Scholar
• Kleihues P, Ohgaki H. Primary and secondary glioblastomas: From concept to clinical diagnosis. Neurooncol 1999; 1: 44–51
   Google Scholar
• Porter AC, Felder CC. The endocannabinoid nervous system: Unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90: 45–60
   PubMed Web of Science ®Google Scholar
• Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975; 55: 597–602
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Sánchez C, Cortés ML, del Pulgar TG, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313–9
   PubMed Web of Science ®Google Scholar
• Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001; 15: 2745–7
   PubMed Web of Science ®Google Scholar
• Guzmán M., Sánchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001; 78: 613–25
   PubMed Web of Science ®Google Scholar
• Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta9 tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006; 1;66(13)6615–21
   PubMedGoogle Scholar
• Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211–9
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131–4
   PubMed Web of Science ®Google Scholar
• Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11: 961–71
   PubMed Web of Science ®Google Scholar
• Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang H-SS. Replacement of the p16/CDKN2 gene suppresses human Glioma cell growth. Cancer Res 1995; 55: 1351–4
   PubMed Web of Science ®Google Scholar
• DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15: 4215–24
   PubMed Web of Science ®Google Scholar
• Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245–62
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Wada H, Yoshida O, Fukushima M, Nonomura M, Nasao M, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 2003; 9: 1453–60
   PubMed Web of Science ®Google Scholar
• Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, Nomura Y. Clinical signification of thymidylate synthase expression in bladder cancer. Int J Urol 2002; 9: 368–76
   PubMedGoogle Scholar
• Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003; 104: 790–5
   PubMedGoogle Scholar
• Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321–4
   PubMed Web of Science ®Google Scholar
• Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, et al. Mutations of the p16 gene in gliomas. Oncogene 1996; 12: 63–7
   PubMed Web of Science ®Google Scholar
• Costello JF, Berger MS, Huang H-JS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996; 56: 2405–10
   PubMed Web of Science ®Google Scholar
• Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WKA, et al. Adenovirus-mediated p16/CDKN2 gene transfer suppress Glioma invasion in vitro. Oncogene 1997; 15: 2049–57
   PubMed Web of Science ®Google Scholar
• Yew PR. Ubiquitin-mediated proteolysis of vertebrate G1- and S phase regulators. J Cell Physiol 2001; 187: 1–10
   PubMedGoogle Scholar
• Campanero MR, Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: Stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci USA 1997; 94: 2221–6
   PubMed Web of Science ®Google Scholar